EXPERT VIEW: Four Priorities For Regulatory Convergence In Asia
This article was originally published in PharmAsia News
The 2015 Asia Regulatory Conference (ARC) held on Feb.4-5 in Taiwan brought together over 250 stakeholders from regulatory, pharmaceutical, academic, civil society, international and non-governmental organizations, including policy experts from Asia. They met on the understanding that no single state, regulatory authority or company within the pharmaceutical industry can meet current regulatory challenges alone.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.